Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio clínico sobre implantes con tecnología TiUltra y componentes protésicos asociados

9 de noviembre de 2026 actualizado por: Nobel Biocare

Un estudio clínico prospectivo, no intervencionista, para evaluar la seguridad, el rendimiento y los beneficios clínicos de los implantes con tecnología TiUltra y componentes protésicos asociados

This is a multicenter, prospective, non-interventional study in which a total of 1000 subjects in need of a single, multiple or full arch restoration in any region of the mouth (healed or extracted) will be treated in up to 30 study centers. The primary aim of this study is to demonstrate non-inferiority of all NobelBiocare TiUltra implants to historic data from NobelActive TiUnite coated implant in terms of marginal bone level change over 5 years after final prosthetic delivery. Eligible subjects who provide their informed consent for participation will be enrolled into one of four groups, each sized to 250 individuals. They will be treated with the corresponding implant system assigned to the group. The allocation into a certain group is only driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic. Each subject will be followed for 5 years after definitive prosthetic placement

Descripción general del estudio

Descripción detallada

Primary Objective: The primary endpoint is to evaluate the change in the marginal bone level from definitive prosthetic placement (baseline) to the 5-year follow-up visit.

Secondary Objective:The secondary objectives of this clinical investigation are:

  • To evaluate the change in the marginal bone level from definitive prosthetic placement (baseline) to 1-year and 3-years follow-up visits
  • To demonstrate cumulative implant survival and success rates from definitive prosthetic placement to 5 years follow-up visit
  • To demonstrate cumulative prosthetic survival and success rates to 5 years follow-up visit
  • To evaluate soft tissue outcome (as measured by bleeding index, plaque index and gingival index) to 5 years from definitive prosthetic placement.
  • To evaluate SADE, USADE, ADE and DD from implant insertion until 5 years follow-up visit.

Study design: This is a multicenter, prospective, non-interventional study in which a total of 1000 subjects in need of a single, multiple or full arch restoration in any region of the mouth (healed or extracted) will be treated in up to 30 study centers. The study devices are divided into four groups:

  • Group 1 (G1): NobelActive TiUltra implants (3.0, NP, RP, WP)
  • Group 2 (G2): NobelParallel CC TiUltra implants (NP, RP; WP)
  • Group 3 (G3): NobelReplace CC TiUltra implants (NP, RP)
  • Group 4 (G4): Nobel Biocare N1 TiUltra TCC implants (NP, RP)

Subjects will be consecutively included provided they meet all of the inclusion criteria and none of the exclusion criteria. Eligible subjects who provide their informed consent for participation will be enrolled into one of four groups, each sized to 250 individuals. They will be treated with the corresponding implant system assigned to the group. The allocation into a certain group is only driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic. Each subject will be followed for 5 years after definitive prosthetic placement . Possible dropouts and withdrawals, as well as possible serious adverse (device) events, will be carefully monitored during the entire study period

Sequence of treatment: As part of the screening process each subject will undergo a pre-treatment standard of care examination to record demographic characteristics and medical history. The subjects will be informed of the treatment possibilities according to clinic standard of care and about the study. Depending on the clinical indication, clinician preferences and desired esthetic solution the subject will be enrolled into one of the four previously described groups (G1 to G4). Implant surgery-, bone and tissue regenerative- and prosthodontic procedures shall be performed according to IFU and standard of care. Implants may be placed in either healed or extraction sites utilizing one-stage or two-stage surgical protocol with immediate, early or delayed loading to restore single missing tooth, partial or fully edentulous jaws. The treating clinician should decide individually when definitive prosthesis installation is suitable for each subject. Standard of care follow-up visits should be scheduled as close as possible to 1-, 3- and 5- years after definitive prosthetic placement, to ascertain a homogenous data set. Deidentified periapical radiographs from each subject visit shall be uploaded to the study eCRF. All images will be forwarded to the core lab for independent analysis. As part of the screening process each subject will undergo a pre-treatment standard of care examination to record demographic characteristics and medical history. The subjects will be informed of the treatment possibilities according to clinic standard of care and about the study.

Depending on the clinical indication, clinician preferences and desired esthetic solution the subject will be enrolled into one of the four previously described groups (G1 to G4). Implant surgery-, bone and tissue regenerative- and prosthodontic procedures shall be performed according to IFU and standard of care. Implants may be placed in either healed or extraction sites utilizing one-stage or two-stage surgical protocol with immediate, early or delayed loading to restore single missing tooth, partial or fully edentulous jaws. The treating clinician should decide individually when definitive prosthesis installation is suitable for each subject.

Study duration: Once the subject has provided written informed consent and fulfilled all inclusion and none of the exclusion criteria, he/she is considered enrolled. Subject enrolment period is expected to take 7 months from time of initiation at each site. Enrolment in each group will stop once the total group size of 250 subjects has been met. The clinical investigation will continue until each subject has been followed for 5-years after final prosthetic delivery.

Tipo de estudio

De observación

Inscripción (Actual)

1000

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Karlstadt am Main, Alemania, 97753
        • DrS - Schöne Zähne - Dr. Scherg Praxis für Implantologie & Ästhetik
      • Melbourne, Australia, 3010
        • Melbourne Dental School The University of Melbourne
    • New South Wales
      • Pyrmont, New South Wales, Australia, 2009
        • Dentartisans Pty ltd
    • Perth
      • West Perth, Perth, Australia, 6005
        • Bc Prosthodontics
      • Vienna, Austria, 1190
        • Implantologie und Ästhetische Zahnheilkunde
      • Vienna, Austria, 1090
        • Akademie für orale Implantologie GmbH & Co
    • Herning
      • Herning, Herning, Dinamarca, 7400
        • Herning Implantat Center
      • Barcelona, España, 08006
        • Clinica Lluch
      • Málaga, España, 29016
        • Clinica Dental Crooke & Laguna
      • Palma de Mallorca, España, 07004
        • Altés & Mesquida
    • Alabama
      • Madison, Alabama, Estados Unidos, 35758
        • Madison Prosthodontics
    • Illinois
      • Arlington Heights, Illinois, Estados Unidos, 60005
        • Northwest Oral and Maxillofacial Surgery
      • Saint Charles, Illinois, Estados Unidos, 60174
        • Midwest Dental Implantology
    • New York
      • New York, New York, Estados Unidos, 10022
        • New York Center for Orthognathic and Maxillofacial Surgery
    • Oregon
      • Tualatin, Oregon, Estados Unidos, 97062
        • Periodontal Associates
      • Tampere, Finlandia, 33200
        • Dental Center Helmiäinen
      • Lyon, Francia, 69002
        • Cabinet du Dr Noharet
      • Montpellier, Francia, 34090
        • BGLP
      • Paris, Francia, 75017
        • IFCIA
      • Cattolica, Italia, 47841
        • Studio Odontoiatrico Specialistico Ban Mancini Fabbri
      • Verona, Italia, 37134
        • UOC di Chirurgia Maxillo-Facciale e Odontoiatria
      • Harstad, Noruega, 9405
        • The Oris Dental Harstad
      • 's-Hertogenbosch, Países Bajos, 5216
        • Staas & Bergmans Zorgvooruwmond B.V.
      • Breda, Países Bajos, 4819
        • ParoBrea- Parodontologie & Implantologie
      • Groningen, Países Bajos, 9713
        • Department of Oral and Maxillofacial Surgery University Medical Center Groningen
      • Lisbon, Portugal, 1600-042
        • Maló Clinic
      • Gothenburg, Suecia, 413 90
        • Folktandvården Västra Götaland, Brånemarkkliniken
      • Malmö, Suecia, 217 72
        • Pequrio AB
      • Egerkingen, Suiza, 4622
        • Dentalspecialist
      • Lucerne, Suiza, 6003
        • Brunner Praxis für Zahnmedizin
      • Oberrieden, Suiza, 8942
        • Centrella Zahnärzte
      • Rorschach, Suiza, 9400
        • Bodensee-Implantat-Zentrum AG

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

N/A

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Subjects will be consecutively included provided they meet all of the inclusion criteria and none of the exclusion criteria.They will be treated with the corresponding implant system assigned to the group. The allocation into a certain group is only driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic. Each subject will be followed for 5 years after definitive prosthetic placement.

If the subject wishes to withdraw from the clinical study, he/she may do so at any time and for any reason during the clinical study. If provided, the reason for withdrawal should be recorded and documented in the subject's medical record and in the eCRF.

Descripción

Inclusion Criteria:

  • Subject signed the informed consent
  • Subject is between 18 and 70 years of age
  • Subjects presented with the need of single, multiple or full arch implant rehabilitation in any region of the mouth.
  • Subject with medical and anatomical conditions that are in accordance with the applicable instructions for use (IFU).
  • Subject with sufficient bone volume for implant placement.
  • Subject is compliant with good oral hygiene as judged by the clinician.

Exclusion Criteria:

  • Anatomical conditions discovered during surgery preventing the use of intended implant system.
  • Subjects with history of allergy or adverse reactions to any materials used
  • Uncontrolled diabetes (subjects with history of diabetes mismanagement and/or known A1c level above 8%)*
  • Heavy smokers (>10 cigarettes per day)
  • Severe bruxism or dysfunctional tendencies
  • Previous oro-maxillo facial radiotheraphy
  • Any ongoing application of interfering medication (steroid therapy, bisphosphonate, etc)
  • Any disorders in the planned implant area such as previous tumors, chronic bone disease or previous radiation.
  • Acute, untreated periodontitis in the planned implantation site or adjacent tissue.
  • Infections in the planned implantation site or adjacent tissue.
  • Documented complete remission of >3 years if history of non-oral cancer.
  • Pregnant or lactating women at the time of implant insertion. *Assessment of A1C level is not required unless it is standard of care at the treating clinic

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: OTHER
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Group 1 (G1): NobelActive TiUltra implants (3.0, NP, RP, WP)

Subjects will be enrolled into Group 1 and treated with NobelActive TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.

Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.

Group 2 (G2): NobelParallel CC TiUltra implants (NP, RP; WP)

Subjects will be enrolled into Group 1 and treated with NobelParallel CC TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.

Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.

Group 3 (G3): NobelReplace CC TiUltra implants (NP, RP)

Subjects will be enrolled into Group 1 and treated with NobelReplace CC TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.

Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.

Group 4 (G4): Nobel Biocare N1 TiUltra TCC implants (NP, RP)

Subjects will be enrolled into Group 1 and treated with Nobel Biocare N1 TiUltra TCC implants , only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.

Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Marginal bone level change
Periodo de tiempo: Definitive prosthetic delivery to 5-years follow-up

The primary endpoint is to evaluate the change in the marginal bone level from definitive prosthetic placement (baseline) to the 5-year follow-up visit.

Definitive prosthetic delivery to 5-years follow-up

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Marginal bone level change
Periodo de tiempo: Definitive Prosthetic delivery to 1-year, Definitive Prosthetic delivery to 3-years

To evaluate the change in the marginal bone level from definitive prosthetic placement (baseline) to 1-year and 3-years follow-up visits

Definitive Prosthetic delivery to 1-year, Definitive Prosthetic delivery to 3-years
Cumulative Survival rate/Cumulative success rate
Periodo de tiempo: Definitive prosthetic delivery to 5-year follow-up

To demonstrate cumulative implant survival and success rates from definitive prosthetic placement to 5 years follow-up visit

Definitive prosthetic delivery to 5-year follow-up
Prsothetic suviival and success rate
Periodo de tiempo: Definitive prosthetic delivery to 5-years follow-up

To demonstrate cumulative prosthetic survival and success rates to 5 years follow-up visit

Definitive prosthetic delivery to 5-years follow-up
Sost tissue outcome- Bleeding index
Periodo de tiempo: Definitive prosthetic delivery to 5-years follow-up

To evaluate soft tissue outcome as measured by bleeding index from definitive prosthetic placement to 5 years follow-up visit

Definitive prosthetic delivery to 5-years follow-up
Sost tissue outcome- Plaque index
Periodo de tiempo: Definitive prosthetic delivery to 5-years follow-up

To evaluate soft tissue outcome as measured by plaque index from definitive prosthetic placement to 5 years follow-up visit.

Definitive prosthetic delivery to 5-years follow-up
Sost tissue outcome- Ginigval index
Periodo de tiempo: Definitive prosthetic delivery to 5-years follow-up

To evaluate soft tissue outcome as measured by gingival index from definitive prosthetic placement to 5 years follow-up visit

Definitive prosthetic delivery to 5-years follow-up
Adverse event
Periodo de tiempo: Implant insertion to 5-years follow-up

To evaluate Serious Adverse Device Effects , Unanticipated Serious Adverse Device Effect , Adverse Device Effects and Device Deficiency from implant insertion until 5 years follow-up visit.

Implant insertion to 5-years follow-up

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

26 de mayo de 2021

Finalización primaria (Estimado)

31 de mayo de 2029

Finalización del estudio (Estimado)

31 de mayo de 2029

Fechas de registro del estudio

Enviado por primera vez

28 de enero de 2021

Primero enviado que cumplió con los criterios de control de calidad

2 de febrero de 2021

Publicado por primera vez (Actual)

3 de febrero de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

13 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • T-192

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir